Gerresheimer on the path to sustainable, profitable growth

Transformation into a growth value as innovation leader

Gerresheimer Global headquarters

Today’s virtual Capital Markets Day, Gerresheimer presented its formula G strategy process and the levers for sustainable, profitable growth. The company described its high-value solutions, investment plans, innovation and digitalization strategy, and ambitious sustainability goals. “We are transforming our Gerresheimer into a growth value as innovation leader and solution provider. That’s the core of our strategy process,” said Dietmar Siemssen, chief executive officer of Gerresheimer.

“Within our strategy process formula G we have set ambitious targets. With the right mindset for growth and by mobilizing the entire company we will achieve the targets. Our new corporate design visualizes the new Gerresheimer, our growth mindset and our passion to innovate constantly for a better life. We are reinventing our company. The transformation is on full steam and I am proud and excited to be part of it.”

Gerresheimer anticipates global megatrends for pharma and healthcare and serves the customers and patients worldwide with innovative solutions and the broadest portfolio of products and solutions. The increasing demand for general vaccinations and self-medication and the shift from small molecules to biologics and biosimilars will boost the market for injectables. Gerresheimer has leading market positions in injectable product solutions such as syringes, vials, pens, and auto-injection devices and will continue to be the partner of choice for pharma and healthcare.

With its global footprint and broad product portfolio, Gerresheimer is well positioned in attractive niche markets. Gerresheimer will expand its global business, focusing on growth regions such as China, India, and South-East Asia.

“We are exploiting excellent business opportunities. In order to benefit from foreseeable market dynamics, we are investing ahead of the curve. Our investment plans include capital expenditures in unique business opportunities coming along with capacity expansions for injectables and contract manufacturing of an auto-injector. We expect cash capex to keep previous year’s level for 2021 and 2022 and converting it into high single-digit revenue growth mid-term,” explained Dr Bernd Metzner, chief financial officer.

Innovative solutions will be a key driver for over proportional growth. Further expansion of the worldwide innovation and competence centers is scheduled, resulting in a global and connected network. “We are driving innovation and digitalization, clearly moving Gerresheimer into a digital and connected world. We will use the shift toward a more patient centric healthcare system to steer our company into more innovative and digital business models,” said Dr Lukas Burkhardt, member of the Management Board.

Ambitious sustainability targets complement the formula G growth strategy. “As well as cementing our position as a good corporate citizen, sustainability is both a growth lever and business opportunity for our company. It is therefore an essential part of our strategy. We have defined very ambitious sustainability targets that set new industry standards,” explained Siemssen.

Gerresheimer confirms the guidance for the financial year 2020 (FXN):

• Revenue growth in the mid-single-digit percentage range
• Adjusted EBITDA margin of around 21%
• Capital expenditure amounting to roughly 12% of revenues
Forecast for the financial year 2021 (core business FXN):
• Revenue growth in the mid-single-digit percentage range
• Adjusted EBITDA margin between 22% to 23%
• Adjusted EPS growth of around 10%
Mid-term (core business FXN):
• Revenue growth of high-single-digit percentage growth
• Adjusted EBITDA margin of around 23%
• Adjusted EPS growth of 10% an annum or more


Please enter your comment!
Please enter your name here